Bemcentinib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Bemcentinib Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: CONDITIONAL GO
Decision memo
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
The central underwriting question is whether Bemcentinib can convert its Small molecule drug profile and AXL x FAM171A2 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Bemcentinib (query alias: Bemcentinib) |
|---|---|
| Modality / target | Small molecule drug; AXL x FAM171A2; AXL inhibitors, FAM171A2 inhibitors |
| Highest global status | Phase 2 |
| Originator | Rigel Pharmaceuticals, Inc. |
| Active developers | Oncoinvent ASA, Rigel Pharmaceuticals, Inc., University of Ulsan |
The MCP disease footprint includes Non-Small Cell Lung Cancer, Pulmonary Fibrosis, Parkinson Disease. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07445048 | Phase 3 | Recruiting | 370 | Primary endpoint not disclosed in English source |
| NCT06516887 | Phase 1/2 | Terminated | 4 | Primary endpoint not disclosed in English source |
| NCT06469138 | Phase 1 | Completed | 6 | Primary endpoint not disclosed in English source |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Tumour Extrinsic Regulation of Neutrophils Sensitize Mesotheliomas to AXL and PD1 Inhibition inMIST3, a Phase II Clinical Trial
Phase 2; n=21; evaluation: Positive. Reported fields: DCR(12-week) = 46.2 % ( 29.2 - 63.8)
Mesothelioma Stratified Therapy (MiST): A Stratified Multi-arm Phase IIa Clinical Trial to Enable Accelerated Evaluation of Targeted Therapies for Relapsed Malignant Mesothelioma
Phase 2; n=186; evaluation: Not stated in English source. Reported fields: Disease Control Rate (DCR) at 12 Weeks Assessed by Modified RECIST 1.1, in Patients With Relapsed Mesothelioma. = 15 Pts ; Disease Control Rate (DCR) at 12 Weeks Assessed by Modified RECIST 1.1, in Patients With Relapsed Mesothelioma. = 14 Pts
Phase 1b/2a Safety and Tolerability Study of Bemcentinib With Pembrolizumab/Carboplatin/Pemetrexed in Subjects With Untreated Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Without/With a STK11 Mutation
Phase 1/2; n=26; evaluation: Not stated in English source. Reported fields: Phase 1b: Number of Participants With Dose Limiting Toxicity (DLT) = 0 Pts ; Phase 1b: Number of Participants With Dose Limiting Toxicity (DLT) = 0 Pts
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Bemcentinib addresses Non-Small Cell Lung Cancer, Pulmonary Fibrosis, Parkinson Disease. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The MCP screen returned 3 matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2024-08-20 | BerGenBio Collaborates with Tempus to Potentially Accelerate Development in STK11m Non-Small Cell Lung Cancer | Phase 1/2 | Financial terms not disclosed |
| 2019-12-03 | Piramal Pharma Solutions Announces Collaboration with BerGenBio on the Development of FDA Fast Track Designated Leukemia Treatment | Phase 2 | Financial terms not disclosed |
| 2011-11-01 | Rigel entered into an exclusive, worldwide research, development and commercialization agreement with BerGenBio for its R428 | Phase 2 | US$3.3M upfront |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Biological target and its use in treating or preventing neurodegenerative diseases”. The milestone feed surfaced a patent-application signal described as “Biomarker for prediction of immunotherapy outcomes and precision treatment strategies and uses thereof”. The milestone feed surfaced a patent-application signal described as “Image-based auxiliary decision-making method, system and equipment for treatment of craniopharyngeal tubuloma”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.
7. Principal risks and diligence gates
- Therapeutic index and off-target toxicity
- Resistance biology and biomarker-defined patient selection
- Differentiation from established and emerging standards
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
CONDITIONAL GO
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 2026-09-16. Counts and status fields may change as source records update.
